IMPACT OF ANTI-HYPERTENSIVE AGENT ON ANTI-DIABETIC DRUG IN DIABETIC AND NON-DIABETIC RATS – ASSESSMENT OF DRUG–DRUG INTERACTIONS

Objectives: The investigation was planned to evaluate pharmacokinetic and pharmacodynamic drug communication of Captopril and Metformin in healthy and diabetic albino Wistar rats succeeding single and many dosage treatments. Methods: Therapeutic doses of captopril and metformin were administered to animal models, blood glucose levels were assessed by glucose oxidase-peroxidase (GOD-POD) method technique, and plasma captopril and metformin amounts were estimated by reversed-phase high-performance liquid chromatography (HPLC) technique to compute the pharmacokinetic attributes. In the present work, the pharmacokinetic and pharmacodynamic interaction between captopril and metformin was evaluated. Pre-clinical investigation might be supportive of evading drug–drug interactions in medical conditions. By means of HPLC, concentration versus time data were plotted for direct extraction of the pharmacokinetic attributes, peak plasma concentrations (Cmax), and time to reach peak concentration (tmax). The linear trapezoidal rule was used in this work to compute AUC from 0 h to 24 h, which is denoted by AUC 0-t. Results: In the determination of fasting serum glucose concentration in normal and streptozotocin-inducted diabetic animals on day 1 and day 8, there was a tremendous decline in the glucose levels in a significant manner (**p<0.001). When captopril alone administered group was compared to the group in combination with metformin on days 1 and 8, there was no significant variance in Cmax, Tmax, AUCo-t, and AUCo-inf. Conclusion: The results concluded from the kinetic analysis revealed that there were no significant interactions in the kinetic parameters of metformin and captopril, both alone and in combination. However, further possible investigations are needed which might be helpful for diabetes.